Annual CFO:
-$359.17M-$71.39M(-24.81%)Summary
- As of today, RXRX annual cash from operations is -$359.17 million, with the most recent change of -$71.39 million (-24.81%) on December 31, 2024.
- During the last 3 years, RXRX annual cash from operations has fallen by -$200.56 million (-126.45%).
- RXRX annual cash from operations is now -691.15% below its all-time high of -$45.40 million, reached on December 31, 2020.
Performance
RXRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFO:
-$76.42M+$55.54M(+42.09%)Summary
- As of today, RXRX quarterly cash from operations is -$76.42 million, with the most recent change of +$55.54 million (+42.09%) on June 30, 2025.
- Over the past year, RXRX quarterly cash from operations has increased by +$5.80 million (+7.06%).
- RXRX quarterly cash from operations is now -198.75% below its all-time high of $77.39 million, reached on March 31, 2022.
Performance
RXRX Quarterly Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$383.03M+$5.80M(+1.49%)Summary
- As of today, RXRX TTM cash from operations is -$383.03 million, with the most recent change of +$5.80 million (+1.49%) on June 30, 2025.
- Over the past year, RXRX TTM cash from operations has dropped by -$51.51 million (-15.54%).
- RXRX TTM cash from operations is now -2049.80% below its all-time high of -$17.82 million, reached on March 31, 2020.
Performance
RXRX TTM Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RXRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -24.8% | +7.1% | -15.5% |
| 3Y3 Years | -126.5% | -24.0% | -388.3% |
| 5Y5 Years | -529.7% | -357.6% | -609.7% |
RXRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -330.0% | at low | -70.8% | +42.1% | -358.6% | +1.5% |
| 5Y | 5-Year | -691.1% | at low | -198.8% | +42.1% | -743.7% | +1.5% |
| All-Time | All-Time | -691.1% | at low | -198.8% | +42.1% | -2049.8% | +1.5% |
RXRX Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$76.42M(+42.1%) | -$383.03M(+1.5%) |
| Mar 2025 | - | -$131.96M(-14.3%) | -$388.83M(-8.3%) |
| Dec 2024 | -$359.17M(-24.8%) | -$115.43M(-94.9%) | -$359.17M(-13.0%) |
| Sep 2024 | - | -$59.23M(+28.0%) | -$317.82M(+4.1%) |
| Jun 2024 | - | -$82.22M(+19.6%) | -$331.52M(-4.7%) |
| Mar 2024 | - | -$102.30M(-38.1%) | -$316.76M(-10.1%) |
| Dec 2023 | -$287.78M(-244.5%) | -$74.08M(-1.6%) | -$287.78M(-11.3%) |
| Sep 2023 | - | -$72.92M(-8.1%) | -$258.45M(-7.7%) |
| Jun 2023 | - | -$67.47M(+8.0%) | -$240.07M(-2.5%) |
| Mar 2023 | - | -$73.32M(-63.8%) | -$234.23M(-180.4%) |
| Dec 2022 | -$83.52M | -$44.75M(+18.0%) | -$83.52M(+16.4%) |
| Sep 2022 | - | -$54.54M(+11.5%) | -$99.93M(-27.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$61.62M(-179.6%) | -$78.44M(-55.4%) |
| Mar 2022 | - | $77.39M(+226.5%) | -$50.47M(+68.2%) |
| Dec 2021 | -$158.61M(-249.4%) | -$61.16M(-85.1%) | -$158.61M(-78.5%) |
| Sep 2021 | - | -$33.05M(+1.8%) | -$88.88M(-18.1%) |
| Jun 2021 | - | -$33.65M(-9.4%) | -$75.29M(-29.1%) |
| Mar 2021 | - | -$30.75M(-458.7%) | -$58.34M(-28.5%) |
| Dec 2020 | -$45.40M(+20.4%) | - | - |
| Dec 2020 | - | $8.57M(+144.1%) | -$45.40M(+15.9%) |
| Sep 2020 | - | -$19.46M(-16.5%) | -$53.97M(-56.4%) |
| Jun 2020 | - | -$16.70M(+6.3%) | -$34.52M(-93.7%) |
| Mar 2020 | - | -$17.82M | -$17.82M |
| Dec 2019 | -$57.04M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual cash from operations?
- What is the all-time high annual cash from operations for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual cash from operations year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly cash from operations?
- What is the all-time high quarterly cash from operations for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly cash from operations year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM cash from operations?
- What is the all-time high TTM cash from operations for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM cash from operations year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual cash from operations?
The current annual cash from operations of RXRX is -$359.17M
What is the all-time high annual cash from operations for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual cash from operations is -$45.40M
What is Recursion Pharmaceuticals, Inc. annual cash from operations year-on-year change?
Over the past year, RXRX annual cash from operations has changed by -$71.39M (-24.81%)
What is Recursion Pharmaceuticals, Inc. quarterly cash from operations?
The current quarterly cash from operations of RXRX is -$76.42M
What is the all-time high quarterly cash from operations for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly cash from operations is $77.39M
What is Recursion Pharmaceuticals, Inc. quarterly cash from operations year-on-year change?
Over the past year, RXRX quarterly cash from operations has changed by +$5.80M (+7.06%)
What is Recursion Pharmaceuticals, Inc. TTM cash from operations?
The current TTM cash from operations of RXRX is -$383.03M
What is the all-time high TTM cash from operations for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM cash from operations is -$17.82M
What is Recursion Pharmaceuticals, Inc. TTM cash from operations year-on-year change?
Over the past year, RXRX TTM cash from operations has changed by -$51.51M (-15.54%)